

Radiomics Opens its first North American office in Toronto, Ontario



LIEGE (BE), April 26th, 2021 -- Radiomics is pleased to announce the official opening of its first North American sales and support office with the support of the Walloon investment support agency AWEX. The new office, established in Toronto, Ontario will kick-start the company's partnerships in the area, better accommodating pharma companies and clinicians' needs through North America-based team members. This global expansion positions Radiomics as one of the few radiomics-based service providers with expertise in several therapeutic areas across multiple imaging modalities with a presence both in North America and Europe. The company plans to establish a third office in China in the coming years.

"The decision to expand into North America was a logical step in our business growth strategy" said Wim Vos, CEO of Radiomics. "Quite a bit of the world's most important drug developers, as well as leading scientist, are located in North America and a presence in Canada will allow us to even better establish relationships with our clients in this territory."

Radiomics' goal is to empower healthcare and drug development trajectories via AI, supporting decision-making with new and more sensitive quantitative insights extracted from standard clinical images. Radiomics is one of the fastest-growing Life Sciences start-ups in Belgium, having grown from 5 people employed at the end of 2019, to more than 30 people in the first quarter of 2021 and will likely meet its target to double its workforce over the next 24 months.

"2021 has been a year of milestones for Radiomics! We've welcomed new team members, adopted a new branding, scaled our technology to new heights, and have been fostering relationships with some of the largest drug development partners in the North American region," said Carlos C. Meca, Chief Commercial Officer. "Establishing Radiomics in Canada will enable us to better serve and continue to foster our pharma and biotech partnerships in North America while also acting as a catalyst for industry backed R&D with local clinicians, scientists, academic hospitals and research institutions" said Hanif Gabrani-Juma, Business Developer for Radiomics in North America

The new office will be inaugurated on May 1st, 2021. Nevertheless, due to the current pandemic situation and the active restrictions in the country, Radiomics is available to host interactions online only. To book a one-to-one meeting with a Radiomics representative in the region or to receive more information, please contact sales@radiomics.bio.

About Radiomics

Radiomics is a Belgian next generation imaging CRO built upon the unparalleled experience of its founders, pioneers of the radiomics science. Radiomics focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Through our proprietary advanced image analysis technology, we aim to unravel the gold mine of hidden data information embedded in standard medical images. Our final goal is to support insight-based decision making for optimizing pharmaceutical and biotech companies' clinical trials and drug development studies and for providing clinicians

with a patient-centered approach based on personalized medicine. With this aim, Radiomics' R&D team is continuously working on new solutions, in collaboration with multiple national and international partners.

Fabrizia Candido

Account and PR Manager

fabrizia.candido@radiomics.bio

